Chapter: Chapter 7: Hypertension — Clinical and Pharmacological Series — Module: HTN-10 — Deep Dive: Hypertension in the Elderly and Isolated Systolic Hypertension Tier: Core Concepts
BEFORE YOU BEGIN
Hypertension in the elderly is the most prevalent cardiovascular condition in the over-65 population and one of the most pharmacologically nuanced. The questions in this set address the unique vascular biology that produces isolated systolic hypertension in aging, the landmark trial evidence that justifies treatment even into the ninth decade of life, the specific drug classes proven effective and those to avoid, and the critical individualization required when frailty, polypharmacy, and orthostatic hypotension complicate the clinical picture. Several questions focus on the pharmacological reasoning behind de-prescribing — a concept as important in elderly hypertension as initiating therapy — and on the specific adverse drug reactions that disproportionately harm older patients. Approach each question with the dual framework of cardiovascular protection and safety in the context of aging physiology.
1. Which of the following best explains the vascular mechanism that produces isolated systolic hypertension (ISH) in aging, and why this mechanism produces widening of pulse pressure rather than combined systolic and diastolic hypertension?
A) ISH in aging results from increased cardiac output from left ventricular hypertrophy — the hypertrophied heart ejects a larger stroke volume, raising systolic BP; diastolic BP is unchanged because venous return is not affected by LVH.
B) ISH in aging results from renal sodium retention and volume expansion — elderly kidneys retain sodium through reduced nephron mass, raising intravascular volume and systolic BP preferentially because the stiff arterial wall cannot accommodate the additional volume during diastole.
C) ISH in aging results from increased peripheral vascular resistance from arteriolar vasoconstriction — elevated SVR raises both systolic and diastolic BP, but elderly patients' reduced cardiac reserve means the diastolic component is partially offset by reduced stroke volume, producing the net appearance of selective systolic elevation.
D) ISH in aging results from age-related arterial stiffness — elastin fragmentation, collagen cross-linking from AGEs, and medial calcification reduce aortic compliance; a stiff aorta cannot buffer the systolic pressure wave (reduced Windkessel effect), causing SBP to rise; simultaneously, the absent elastic recoil of a stiff aorta fails to maintain diastolic pressure between heartbeats, causing DBP to fall or remain unchanged; the combination produces rising SBP with falling or stable DBP — widened pulse pressure.
E) ISH in aging results from autonomic dysfunction — reduced vagal tone and increased resting sympathetic outflow in elderly patients selectively raises systolic BP through tachycardia-mediated increases in cardiac output; diastolic BP falls because sympathetic venoconstriction is also reduced.
ANSWER: D
Rationale:
The mechanism of ISH in aging is fundamentally vascular — driven by arterial stiffness rather than by neurohormonal activation, volume expansion, or cardiac output changes. The normal aorta provides the Windkessel effect: during systole, the compliant aorta expands to absorb part of the stroke volume, limiting the peak systolic pressure; during diastole, the elastic recoil of the aortic wall generates pressure that maintains DBP and drives coronary perfusion. With aging, elastin fibers in the aortic wall fragment and are replaced by stiffer collagen; advanced glycation end products (AGEs) cross-link collagen molecules further reducing compliance; and medial calcification contributes additional stiffness. The result: the stiff aorta cannot expand during systole (systolic pressure rises steeply, unattenuated), and provides no elastic recoil during diastole (diastolic pressure is not maintained). SBP rises while DBP is unchanged or falls, producing a widened pulse pressure — the defining hemodynamic feature of ISH.
Option A: Option A is incorrect because LVH does not primarily drive ISH in aging — LVH is a consequence of chronic hypertension in the elderly, not its cause; and increased stroke volume from LVH would raise both systolic and diastolic pressure.
Option B: Option B is incorrect because while renal sodium retention contributes to some hypertension in the elderly, it does not explain the selective systolic elevation and pulse pressure widening that characterizes ISH — volume expansion raises both systolic and diastolic pressure proportionally.
Option C: Option C is incorrect because increased SVR from arteriolar vasoconstriction raises both systolic and diastolic pressure — it produces combined hypertension, not ISH with pulse pressure widening.
Option E: Option E is incorrect because while autonomic changes occur with aging, tachycardia-driven systolic hypertension from reduced vagal tone is not the primary mechanism of ISH — many elderly patients with ISH have low-normal or low heart rates.
2. The SHEP trial was a landmark study in elderly hypertension. Which of the following correctly summarizes the key findings and their pharmacological significance?
A) SHEP enrolled 4,736 patients aged 60 years or older with ISH (SBP 160–219 mmHg, DBP below 90 mmHg) and randomized them to chlorthalidone-based therapy versus placebo — active treatment produced a 36% reduction in stroke, 32% reduction in major cardiovascular events, 54% reduction in left ventricular failure, and 27% reduction in coronary events; SHEP established for the first time that treating ISH in the elderly with a thiazide-like diuretic produced substantial cardiovascular benefit, confirming chlorthalidone as a cornerstone agent for ISH.
B) SHEP enrolled patients aged 80 years or older and demonstrated that treating ISH with atenolol reduced all-cause mortality by 21% and heart failure by 64%; SHEP established beta-blockers as the preferred first-line agent for ISH in the very elderly.
C) SHEP enrolled patients with combined systolic and diastolic hypertension and demonstrated that chlorthalidone reduced stroke risk by 36%; the trial does not specifically address ISH because the inclusion criteria required both elevated systolic and diastolic BP.
D) SHEP demonstrated that treating elderly ISH with chlorthalidone was beneficial but only for patients below age 75; above age 75, active treatment was associated with increased adverse events without cardiovascular benefit.
E) SHEP was the first trial to demonstrate that amlodipine was superior to chlorthalidone for stroke prevention in elderly ISH; its findings established DHP CCBs as the pharmacological cornerstone of elderly hypertension treatment.
ANSWER: A
Rationale:
The SHEP trial (Systolic Hypertension in the Elderly Program, 1991) enrolled 4,736 patients aged 60 years or older with ISH — defined as SBP 160–219 mmHg with DBP below 90 mmHg — and randomized them to active treatment (step 1: chlorthalidone 12.5–25 mg; step 2: add atenolol or reserpine if needed) versus placebo. Active treatment produced landmark reductions: 36% reduction in stroke (the primary endpoint), 32% reduction in major cardiovascular events, 54% reduction in heart failure hospitalizations, and 27% reduction in coronary events. SHEP established three foundational principles: that ISH in the elderly is treatable and treatment produces substantial cardiovascular benefit; that thiazide-like diuretics (chlorthalidone) are effective first-line agents for ISH; and that the cardiovascular risk of ISH in elderly patients is large enough that treatment benefits substantially outweigh risks in non-frail patients.
Option B: Option B is incorrect because SHEP enrolled patients aged 60 and older (not only 80+), used chlorthalidone (not atenolol) as the primary agent, and the HYVET trial — not SHEP — established the very elderly (80+) evidence base and showed mortality and heart failure benefit.
Option C: Option C is incorrect because SHEP specifically enrolled patients with ISH (isolated systolic hypertension with DBP below 90 mmHg) — it addressed ISH directly and is the landmark trial for this specific phenotype.
Option D: Option D is incorrect because SHEP did not show age-stratified benefit reversal above 75 — treatment benefit was not specifically limited to patients below 75; the trial supported treatment across the enrolled age range.
Option E: Option E is incorrect because SHEP tested chlorthalidone (not amlodipine) as its primary agent — the Syst-Eur trial (not SHEP) established DHP CCBs (nitrendipine) as effective for ISH in the elderly.
3. The HYVET trial specifically addressed treatment of hypertension in patients aged 80 years or older. Which of the following correctly describes the key HYVET findings and their clinical significance?
A) HYVET demonstrated that treating hypertension in patients aged 80 or older increased all-cause mortality by 15% compared to placebo — treatment was harmful in the very elderly and HYVET established that antihypertensive therapy should be withheld above age 80.
B) HYVET demonstrated benefit with aggressive targets below 120 mmHg systolic in patients aged 80 or older, consistent with SPRINT; both trials used the same BP measurement methodology, making their results directly comparable.
C) HYVET enrolled 3,845 patients aged 80 or older with SBP 160 mmHg or higher and randomized them to indapamide 1.5 mg SR ± perindopril 2–4 mg versus placebo; active treatment produced a 30% reduction in stroke (primary endpoint, trend), 21% reduction in all-cause mortality, 64% reduction in heart failure, and 23% reduction in cardiovascular death; crucially, serious adverse events were fewer in the active treatment group than placebo, demonstrating that treatment is well-tolerated and beneficial in the very elderly; the mean achieved SBP in the active arm was 143.5 mmHg.
D) HYVET enrolled patients aged 80 or older and demonstrated that amlodipine-based therapy reduced all-cause mortality significantly more than indapamide, establishing DHP CCBs as the preferred class for the very elderly; indapamide was the inferior comparator.
E) HYVET found no significant reduction in stroke or mortality in patients aged 80 or older but demonstrated a significant reduction in cognitive decline — establishing that the primary benefit of antihypertensive treatment in the very elderly is dementia prevention rather than cardiovascular protection.
ANSWER: C
Rationale:
HYVET (Hypertension in the Very Elderly Trial, 2008) enrolled 3,845 patients aged 80 or older (mean age 83.6 years) with sustained SBP of 160 mmHg or higher and randomized them to active treatment (indapamide 1.5 mg sustained-release, with perindopril 2–4 mg added if needed to achieve the target SBP of 150 mmHg) versus placebo. The trial was stopped early due to clear benefit in the active treatment arm. Key results: 30% reduction in stroke (primary endpoint, p=0.06 — a trend that did not quite reach statistical significance but was clinically meaningful); 21% reduction in all-cause mortality (statistically significant, p=0.02); 64% reduction in heart failure; 23% reduction in cardiovascular death. The mean achieved SBP in the active treatment group was 143.5 mmHg, confirming that moderate SBP lowering (not aggressive below-120 targeting) was sufficient for benefit. A particularly important finding was that serious adverse events were actually fewer in the treated group than in the placebo group — directly refuting concerns that antihypertensive treatment in the very elderly was too dangerous. HYVET established that treating hypertension in patients aged 80 or older with indapamide ± perindopril is both beneficial and safe.
Option A: Option A is incorrect because HYVET demonstrated benefit, not harm — all-cause mortality was reduced by 21% with active treatment; the trial was stopped early for benefit, not harm.
Option B: Option B is incorrect because HYVET used a target of 150 mmHg SBP (not below 120 mmHg); SPRINT used automated unattended BP measurement producing readings approximately 5–10 mmHg lower than standard office measurement — the methodologies are not directly comparable.
Option D: Option D is incorrect because HYVET was not a head-to-head comparison of amlodipine versus indapamide — it was active treatment (indapamide-based) versus placebo; amlodipine was not a study arm.
Option E: Option E is incorrect because HYVET did demonstrate significant reductions in stroke and mortality — particularly the 21% all-cause mortality reduction which was statistically significant; cognitive decline prevention was a secondary observation, not the primary finding.
4. Which of the following correctly explains why pulse pressure widens in isolated systolic hypertension and why a widened pulse pressure independently predicts cardiovascular risk?
A) Pulse pressure widens in ISH because elderly patients have increased cardiac output from compensatory left ventricular hypertrophy — the larger stroke volume ejected by the hypertrophied heart raises peak systolic pressure while resting diastolic pressure is maintained by intact vascular tone; pulse pressure predicts cardiovascular risk because it reflects the degree of LVH.
B) Pulse pressure widens in ISH because age-related arterial stiffness impairs the Windkessel effect — the stiff aorta cannot buffer the systolic pressure wave (raising SBP) and provides no elastic recoil to maintain diastolic pressure between beats (DBP falls or is unchanged); a pulse pressure above 60–70 mmHg in elderly patients predicts particularly high cardiovascular event rates because it reflects the severity of aortic stiffness, which directly increases left ventricular afterload, promotes LV hypertrophy, reduces coronary diastolic perfusion pressure, and is an independent marker of arterial aging that predicts stroke, MI, and heart failure beyond systolic BP alone.
C) Pulse pressure widens in ISH because elderly patients develop relative bradycardia — the longer diastolic filling time allows greater stroke volume accumulation, which when ejected produces a higher systolic peak; diastolic BP falls because the prolonged diastolic phase allows more complete arterial runoff; pulse pressure predicts cardiovascular risk because it serves as a surrogate for heart rate.
D) Pulse pressure is simply the arithmetic difference between systolic and diastolic BP and has no independent predictive value for cardiovascular outcomes beyond its component measurements — pulse pressure is listed in guidelines only as a diagnostic convenience for identifying ISH, not as a risk marker.
E) Pulse pressure widens in ISH because elderly patients have increased peripheral vascular resistance that disproportionately raises systolic BP — the higher SVR creates a back-pressure during systole that amplifies the pressure wave; diastolic BP falls because alpha-adrenergic tone decreases at night, reducing baseline vascular resistance; pulse pressure predicts risk because it reflects SVR variability.
ANSWER: B
Rationale:
The widening of pulse pressure in ISH is a direct hemodynamic consequence of age-related arterial stiffness, and its independent predictive value for cardiovascular outcomes is well-established. The normal aorta provides the Windkessel effect: during systole, the compliant aortic wall distends to absorb part of the stroke volume, limiting peak SBP; during diastole, the elastic recoil of the aorta maintains DBP and drives coronary perfusion. With age, elastin fragmentation, collagen cross-linking by advanced glycation end products (AGEs), and medial calcification progressively stiffen the aortic wall. The stiff aorta cannot buffer the systolic pressure wave — SBP rises steeply. It cannot recoil elastically — DBP is not maintained. The result is a widened pulse pressure. The clinical importance of wide pulse pressure (above 60–70 mmHg in elderly patients) extends beyond its diagnostic role: it directly reflects the severity of aortic stiffness, which increases LV afterload (the LV must work against a stiff aorta), promotes concentric LV hypertrophy, reduces coronary diastolic perfusion pressure (risking myocardial ischemia, particularly in patients with CAD), and independently predicts stroke, MI, heart failure, and cardiovascular death in multiple large cohort studies and trial subgroup analyses.
Option A: Option A is incorrect because the primary mechanism of pulse pressure widening in ISH is arterial stiffness, not increased cardiac output from LVH — LVH is a consequence of chronic hypertension, not a cause of pulse pressure widening; and cardiac output is not systematically elevated in elderly ISH.
Option C: Option C is incorrect because relative bradycardia does not drive pulse pressure widening in ISH — the mechanism is arterial stiffness, not heart rate-mediated changes in stroke volume accumulation.
Option D: Option D is incorrect because pulse pressure has substantial independent predictive value for cardiovascular outcomes beyond its component systolic and diastolic measurements — multiple studies including the Framingham Heart Study have established pulse pressure as an independent predictor.
Option E: Option E is incorrect because ISH is characterized by reduced aortic compliance (stiffness), not by increased peripheral vascular resistance as the primary mechanism — SVR is not the dominant driver of pulse pressure widening in elderly ISH.
5. A 77-year-old woman with ISH is started on chlorthalidone 12.5 mg daily. Four weeks later she presents with lethargy and confusion. Serum sodium is 124 mEq/L. Which of the following best explains the mechanism of thiazide-induced hyponatremia and why elderly women are at highest risk?
A) Thiazide diuretics cause hyponatremia by directly inhibiting ADH release from the hypothalamus — chlorthalidone blocks vasopressin V2 receptors, producing a transient diabetes insipidus-like state followed by a rebound oversecretion of ADH that causes free water retention and dilutional hyponatremia.
B) Thiazide diuretics cause hyponatremia by inhibiting aldosterone, producing simultaneous sodium wasting and free water retention through mineralocorticoid receptor blockade — the mechanism is identical to spironolactone-induced hyponatremia; elderly women are at highest risk because their aldosterone levels are already reduced.
C) Thiazide diuretics cause hyponatremia by directly stimulating aquaporin-2 channels in the collecting duct, causing water retention independent of ADH; elderly women are at highest risk because their collecting duct aquaporin-2 expression is upregulated by estrogen deficiency.
D) Thiazide diuretics cause hyponatremia by directly blocking sodium channels in the proximal tubule, producing massive sodium wasting that overwhelms the body's sodium conservation mechanisms; the resulting hyponatremia is not dilutional but purely due to sodium depletion without any water retention component.
E) Thiazide diuretics inhibit the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, causing natriuresis; volume contraction from sodium loss activates baroreceptors, stimulating ADH release; ADH drives free water retention in the collecting duct, producing dilutional hyponatremia; elderly women are at highest risk because smaller total body water and sodium compartments mean a given degree of sodium loss produces a proportionally larger fall in serum sodium, and because estrogen may potentiate ADH activity; chlorthalidone carries higher hyponatremia risk than HCTZ due to its longer half-life and more sustained natriuresis.
ANSWER: E
Rationale:
Thiazide-induced hyponatremia follows a well-characterized two-step pharmacological mechanism. Step 1: thiazide and thiazide-like diuretics (chlorthalidone, indapamide) inhibit the NCC (sodium-chloride cotransporter) in the distal convoluted tubule, blocking sodium reabsorption at this site and producing urinary sodium loss (natriuresis). Step 2: the resulting volume contraction is sensed by arterial baroreceptors, which stimulate ADH (arginine vasopressin) release from the hypothalamic-neurohypophyseal axis. ADH acts on V2 receptors in the collecting duct principal cells, inserting aquaporin-2 water channels and driving free water reabsorption. The net result: sodium is lost while free water is retained — dilutional hyponatremia. Elderly women are at particularly high risk because: smaller total body water (lean body mass decreases with age) means the same sodium loss produces a proportionally larger fall in plasma sodium concentration; smaller total body sodium compartment amplifies the proportional sodium deficit; estrogen may potentiate ADH sensitivity (postmenopausal women lose this protection); and low dietary sodium intake in many elderly women reduces the sodium reserve. Chlorthalidone has a longer half-life (40–60 hours) and more sustained diuretic effect than HCTZ, producing greater cumulative natriuresis and higher hyponatremia risk — hence the recommendation to start at 6.25–12.5 mg in elderly patients with sodium monitoring within 2–4 weeks.
Option A: Option A is incorrect because thiazides do not block vasopressin V2 receptors — they act on NCC in the distal convoluted tubule; and the mechanism does not involve direct ADH secretion inhibition followed by rebound oversecretion.
Option B: Option B is incorrect because thiazides do not inhibit aldosterone — their primary action is NCC inhibition in the DCT; spironolactone and eplerenone block mineralocorticoid receptors but thiazides do not.
Option C: Option C is incorrect because thiazides do not directly stimulate aquaporin-2 channels — water retention is mediated indirectly through ADH stimulation from volume contraction, not through direct aquaporin activation.
Option D: Option D is incorrect because thiazides act on the NCC in the distal convoluted tubule, not on sodium channels in the proximal tubule; and the hyponatremia is dilutional (sodium loss plus water retention), not purely sodium-depleting.
6. Which of the following correctly describes why beta-blockers are not preferred as first-line antihypertensives for uncomplicated ISH in the elderly, and when a beta-blocker would be appropriate?
A) Beta-blockers are not preferred for ISH in the elderly because they increase pulse pressure — by slowing heart rate, they increase stroke volume and worsen the systolic pressure elevation that is the dominant feature of ISH; they are never appropriate in any elderly hypertensive patient.
B) Beta-blockers are not preferred for ISH because they cause hyperkalemia — the beta-2 receptor blockade impairs potassium uptake into skeletal muscle cells, producing dangerous hyperkalemia in elderly patients whose renal potassium excretion is already reduced; they are appropriate only when potassium is below 4.0 mEq/L.
C) Beta-blockers are not preferred for ISH in the elderly because they are ineffective at lowering blood pressure in this population — beta-blockade reduces cardiac output and heart rate but has no effect on systolic BP in elderly patients with low-renin hypertension driven by arterial stiffness; they provide no hemodynamic benefit whatsoever in ISH.
D) Beta-blockers are not preferred as first-line for uncomplicated ISH in the elderly because they are less effective at reducing systolic BP in low-renin ISH driven by arterial stiffness rather than neurohormonal activation; they carry disproportionate adverse effects in the elderly including fatigue, exercise intolerance, falls risk from reduced heart rate reserve, depression, sexual dysfunction, and cold extremities; and they lack the specific trial evidence in ISH that thiazide-like diuretics and DHP CCBs have from SHEP and Syst-Eur; a beta-blocker is appropriate when a compelling indication is present — HFrEF, post-MI, or rate control in atrial fibrillation — in which case a cardioselective agent such as bisoprolol or nebivolol is preferred over atenolol.
E) Beta-blockers are not preferred for ISH in the elderly because they cause rebound hypertension on abrupt discontinuation that is more severe and prolonged in elderly patients than in younger patients — the risk of discontinuation outweighs any antihypertensive benefit; they are appropriate only in patients who will have continuous 24-hour supervision to ensure uninterrupted dosing.
ANSWER: D
Rationale:
Beta-blockers occupy a clearly delineated but limited role in elderly hypertension. For uncomplicated ISH — the dominant hypertension phenotype in elderly patients — they are not first-line agents for several pharmacological and clinical reasons. Mechanistically, elderly ISH is driven primarily by arterial stiffness and reduced aortic compliance rather than by neurohormonal activation (elevated renin, increased sympathetic drive). Beta-1 blockade reduces heart rate and cardiac output but does not substantially address the underlying stiffness — it is less effective at reducing systolic BP than thiazide-like diuretics and DHP CCBs in this context, both of which have landmark ISH-specific trial evidence (SHEP for chlorthalidone, Syst-Eur for nitrendipine). Clinically, beta-blockers carry adverse effects that disproportionately harm the elderly: fatigue and exercise intolerance reduce physical activity and accelerate deconditioning; reduced heart rate reserve impairs the cardiovascular response to orthostatic position change, increasing falls risk; depression, sexual dysfunction, cold extremities, and sleep disturbance affect quality of life; and abrupt withdrawal risk is heightened in elderly patients with irregular medication access. When a compelling indication is present — HFrEF (survival benefit established in MERIT-HF for metoprolol succinate, CIBIS-II for bisoprolol, COPERNICUS for carvedilol), post-MI, or AF rate control — a beta-blocker is appropriate and should be used; cardioselective agents (bisoprolol, nebivolol) are preferred over atenolol in elderly patients because atenolol is renally eliminated (accumulates in CKD), demonstrated inferior outcomes compared to losartan in the LIFE trial, and has more pronounced bradycardia risk.
Option A: Option A is incorrect because beta-blockers do not increase pulse pressure — slowing heart rate reduces stroke volume somewhat, and the net effect on systolic BP is modest reduction rather than increase; and beta-blockers are not never appropriate in elderly hypertensives.
Option B: Option B is incorrect because while non-selective beta-blockade can impair potassium uptake into cells, hyperkalemia is not the primary reason beta-blockers are not preferred for ISH in the elderly; and the potassium threshold described is not a clinical criterion for use.
Option C: Option C is incorrect because beta-blockers do have some antihypertensive effect even in elderly ISH — they are less effective but not completely ineffective; and stating they provide no hemodynamic benefit whatsoever misrepresents the pharmacology.
Option E: Option E is incorrect because while rebound hypertension on abrupt withdrawal is a real concern, it is not the primary reason beta-blockers are not first-line for ISH in the elderly — the reasons are efficacy and adverse effect profile; and continuous supervision is not the clinical criterion for their use.
7. Which of the following correctly describes the SPRINT trial findings in elderly patients aged 75 or older and the important methodological caveat that affects interpretation of its blood pressure targets?
A) SPRINT's elderly subgroup (n=2,636, age ≥75 years) showed that intensive SBP control (target below 120 mmHg) reduced composite cardiovascular events by 34% and all-cause mortality by 33% compared to standard control (target below 140 mmHg); rates of serious adverse events including AKI, syncope, and electrolyte disturbances were higher with intensive treatment; critically, SPRINT used automated unattended BP measurement (AOBP), which produces readings approximately 5–10 mmHg lower than standard office BP — SPRINT's 120 mmHg target corresponds to approximately 130 mmHg by conventional measurement, making direct comparison with other guideline targets require this adjustment.
B) SPRINT's elderly subgroup found no benefit of intensive SBP control below 120 mmHg in patients aged 75 or older — the cardiovascular benefit seen in younger patients was completely eliminated by increased adverse events in the elderly subgroup; SPRINT established that intensive targets are harmful above age 75.
C) SPRINT used standard office BP measurement identical to all other landmark trials including SHEP and HYVET, allowing direct numeric comparison of target BPs across all three trials; SPRINT's 120 mmHg target is directly equivalent to the 143.5 mmHg achieved in HYVET's active treatment arm.
D) SPRINT demonstrated that all elderly patients, including those with frailty and slow gait speed, benefited equally from intensive SBP control below 120 mmHg — frailty did not modify the treatment effect and should not be used to individualize BP targets in the elderly.
E) SPRINT enrolled patients aged 75 or older with ISH specifically (DBP below 90 mmHg) — its findings apply only to elderly patients with ISH and cannot be generalized to elderly patients with combined systolic and diastolic hypertension.
ANSWER: A
Rationale:
The SPRINT elderly subgroup analysis (published separately in JAMA 2016, Williamson et al.) examined the 2,636 participants aged 75 or older who were enrolled in SPRINT. Intensive treatment (targeting SBP below 120 mmHg by AOBP) versus standard treatment (targeting below 140 mmHg) in this elderly subgroup produced: 34% reduction in composite cardiovascular events and 33% reduction in all-cause mortality — both statistically significant and numerically larger than in the overall trial population. This demonstrated that cardiovascular benefit from intensive BP lowering extends to the elderly and very elderly populations, complementing HYVET's findings. However, intensive treatment was associated with higher rates of serious adverse events including acute kidney injury, syncope, and electrolyte disturbances — the benefit-risk calculation therefore requires individualization. The critical methodological caveat: SPRINT used automated office BP measurement (AOBP — the patient sits alone in a room, multiple automated readings taken without a clinician present), which consistently produces values approximately 5–10 mmHg lower than conventional attended office BP measurement. SPRINT's stated target of 120 mmHg AOBP corresponds to approximately 130 mmHg by standard measurement — a distinction essential when translating SPRINT results to clinical practice using conventional BP measurement.
Option B: Option B is incorrect because SPRINT's elderly subgroup did show significant cardiovascular and mortality benefit with intensive treatment — the subgroup showed even larger relative risk reductions than the overall trial; the adverse event rate was higher but the benefit-risk remained favorable in non-frail elderly patients.
Option C: Option C is incorrect because SPRINT's measurement methodology (AOBP) is fundamentally different from the standard attended office BP used in SHEP and HYVET — direct numeric comparison of the BP targets is not valid; the 120 mmHg AOBP target corresponds to approximately 130 mmHg by conventional measurement.
Option D: Option D is incorrect because SPRINT's gait speed subgroup analysis suggested that benefit may be attenuated in patients with slow gait speed (a frailty marker) — the trial supported that frailty should modify BP target individualization, not that all elderly patients benefit equally.
Option E: Option E is incorrect because SPRINT did not restrict enrollment to ISH specifically — it included elderly patients with a range of hypertension phenotypes, not limited to those with DBP below 90 mmHg.
8. Which of the following correctly describes the J-curve phenomenon in elderly hypertension and its clinical management implications?
A) The J-curve in elderly hypertension refers to the finding that patients with very high systolic BP (above 200 mmHg) have paradoxically lower cardiovascular risk than those with moderate elevation (160–180 mmHg) — antihypertensive treatment is therefore most urgent at moderate SBP elevations and less critical at extreme elevations.
B) The J-curve phenomenon means that there is no safe lower limit for BP in elderly patients — any reduction in BP, regardless of magnitude, increases cardiovascular risk; elderly patients should never have their BP targeted below pretreatment values.
C) The J-curve phenomenon describes the observation that excessive lowering of BP — particularly DBP — is associated with worse cardiovascular outcomes, most prominently in patients with established CAD or wide pulse pressure; coronary perfusion occurs during diastole and depends on adequate DBP; in elderly patients, a DBP below 65–70 mmHg — especially in those with established CAD — increases myocardial ischemia risk; the clinical implication is to avoid reducing DBP below 65 mmHg and to monitor for symptoms of coronary underperfusion (angina, dyspnea, pre-syncope) when intensifying antihypertensive therapy.
D) The J-curve in elderly hypertension refers to the relationship between antihypertensive drug dose and adverse events — at low doses, adverse events increase due to insufficient BP control causing end-organ damage; at high doses, adverse events increase due to drug toxicity; the optimal dose is the midpoint between these extremes.
E) The J-curve phenomenon is relevant only in patients with heart failure — in elderly hypertensive patients without heart failure, there is a linear relationship between BP reduction and cardiovascular outcome improvement with no lower limit of benefit; aggressive BP lowering to below 120/60 mmHg is safe in the absence of HFrEF.
ANSWER: C
Rationale:
The J-curve phenomenon in hypertension management refers to the curvilinear relationship between achieved DBP and cardiovascular outcomes — outcomes worsen both when DBP is too high (untreated hypertension) and when DBP is excessively lowered. In elderly patients with ISH and wide pulse pressure, the clinical relevance of the J-curve is particularly pronounced. Coronary perfusion occurs predominantly during diastole — the heart muscle is perfused when the myocardium is relaxed, and the perfusion pressure driving coronary blood flow is the diastolic pressure minus the ventricular end-diastolic pressure. When DBP is reduced below approximately 65–70 mmHg in elderly patients with established coronary artery disease — who frequently have fixed coronary stenoses and reduced coronary autoregulatory reserve — myocardial ischemia risk increases. This is especially relevant in elderly ISH patients with very wide pulse pressures: their DBP is already low (e.g., 65–70 mmHg) and aggressive antihypertensive treatment targeting SBP reduction may further reduce an already marginal DBP. The practical clinical guidance is to avoid reducing DBP below 65 mmHg and to monitor for angina, dyspnea, dizziness, or pre-syncope when intensifying therapy in elderly CAD patients.
Option A: Option A is incorrect because the J-curve refers to the relationship between excessively low (not excessively high) BP and adverse outcomes — very high BP does not produce paradoxically lower risk; the J-curve is about the lower extreme, not the upper.
Option B: Option B is incorrect because the J-curve identifies a specific lower threshold of concern (particularly for DBP below 65–70 mmHg in CAD patients), not a blanket prohibition on any BP lowering; the risk-benefit balance of treating hypertension in the elderly is clearly favorable as established by SHEP, Syst-Eur, and HYVET.
Option D: Option D is incorrect because the J-curve refers to BP levels and outcomes, not to the relationship between drug dose and adverse events — dose-related adverse effects follow different pharmacological principles.
Option E: Option E is incorrect because the J-curve is not limited to heart failure — it is most clearly demonstrated in patients with CAD and wide pulse pressure; the claim that aggressive lowering to below 120/60 mmHg is safe in elderly patients without HFrEF contradicts the evidence from the J-curve literature.
9. Which of the following correctly describes how frailty should modify antihypertensive treatment targets and prescribing strategy in the elderly?
A) Frailty has no pharmacological relevance to antihypertensive prescribing — the same BP target of below 130/80 mmHg (ACC/AHA 2017) should be applied uniformly to all elderly patients regardless of frailty status, as the cardiovascular risk reduction benefit is identical in frail and non-frail populations.
B) Frailty significantly modifies the risk-benefit calculation for antihypertensive treatment in the elderly — fit elderly patients (Clinical Frailty Scale 1–3) can be treated to below 130 mmHg SBP with evidence support from SPRINT; pre-frail patients (CFS 4–5) warrant standard targets around 140 mmHg with careful adverse effect monitoring; frail elderly patients (CFS 6–8) should have treatment individualized with a focus on quality of life, fall prevention, and symptom burden rather than tight numeric targets; de-prescribing should be actively considered in patients experiencing falls, orthostatic hypotension, or declining functional status attributable to antihypertensive therapy.
C) The appropriate response to frailty in elderly hypertensive patients is to increase the number of antihypertensive agents rather than to relax targets — frail patients have higher cardiovascular risk and therefore require more aggressive BP lowering with more drug classes to achieve risk reduction proportional to their elevated baseline risk.
D) Frailty assessment tools (Fried phenotype, Clinical Frailty Scale, gait speed) cannot reliably predict which elderly patients will benefit from antihypertensive treatment — clinicians should ignore frailty assessments and use only chronological age as the criterion for adjusting BP targets.
E) In frail elderly patients, antihypertensive therapy should always be discontinued completely — frailty is defined by reduced physiological reserve, and any pharmacological BP lowering in frail patients carries unacceptable adverse effect risk that outweighs all cardiovascular benefit; cessation of all antihypertensives is mandatory when any frailty criterion is met.
ANSWER: B
Rationale:
Frailty — defined by reduced physiological reserve, vulnerability to stressors, and cumulative decline across multiple organ systems — fundamentally modifies the risk-benefit calculation for antihypertensive treatment intensity in the elderly. The Fried frailty phenotype (five criteria: unintentional weight loss, exhaustion, weak grip strength, slow walking speed, low physical activity; frail = three or more criteria) and the Clinical Frailty Scale (CFS, 1–9) are the most validated assessment tools. Their pharmacological implications: fit elderly patients (CFS 1–3, no frailty criteria) have the physiological reserve to tolerate intensive BP lowering and the life expectancy to derive cardiovascular benefit; evidence from SPRINT elderly subgroup supports targeting below 130 mmHg SBP in this group. Pre-frail patients (CFS 4–5) have reduced reserve; standard targets around 140 mmHg (consistent with ESH 2023 guidance for the very elderly) with careful monitoring for adverse effects are appropriate. Frail patients (CFS 6–8) have severely limited reserve — aggressive BP targets risk falls, orthostatic hypotension, AKI, and cognitive impairment; individualized goals prioritizing quality of life, symptom reduction, and fall prevention are more appropriate than numeric BP targets; active de-prescribing of antihypertensives causing harm should be considered.
Option A: Option A is incorrect because frailty has substantial pharmacological relevance — the SPRINT data itself showed that benefit may be attenuated in patients with slow gait speed; uniform application of below 130/80 mmHg to all elderly patients regardless of frailty disregards individualized prescribing principles.
Option C: Option C is incorrect because the response to frailty is relaxation of targets and simplification of regimens, not escalation — frail patients are at greatest risk from polypharmacy-related adverse effects; more agents in a frail patient increases harm risk without proportional benefit.
Option D: Option D is incorrect because frailty assessment tools have substantial evidence supporting their clinical utility in predicting treatment tolerance and risk in elderly patients — gait speed in particular has been validated as a predictor of treatment outcomes and adverse event risk.
Option E: Option E is incorrect because complete antihypertensive discontinuation is not mandatory in all frail patients — de-prescribing is a considered clinical process involving shared decision-making; some frail patients with very high baseline BP may still benefit from modest BP reduction, particularly if they are not experiencing drug-related adverse effects.
10. Which of the following correctly describes why amlodipine is specifically preferred over other DHP CCBs for ISH management in elderly patients?
A) Amlodipine is preferred over other DHP CCBs because it is the only DHP CCB proven in a head-to-head trial to reduce stroke and cardiovascular events more than nifedipine or felodipine in elderly ISH patients — the amlodipine-specific trial data make it uniquely appropriate.
B) Amlodipine is preferred over other DHP CCBs because it has renoprotective properties equivalent to ACEi and ARBs — its calcium channel blockade in the afferent arteriole reduces glomerular pressure and proteinuria, making it particularly appropriate for elderly patients with CKD and albuminuria.
C) Amlodipine is preferred over other DHP CCBs because it has negative chronotropic properties — unlike other DHP CCBs, amlodipine slows the heart rate, which in combination with BP lowering provides superior cardiovascular protection in elderly patients with atrial fibrillation.
D) Amlodipine is preferred over other DHP CCBs exclusively because of its lower cost and once-daily formulation — its pharmacological properties are identical to all other DHP CCBs and the preference is administrative rather than pharmacological.
E) Amlodipine is preferred for ISH in the elderly primarily because of its long half-life of 35–50 hours — the very long half-life provides smooth, sustained 24-hour BP control without significant BP variability between doses, reduces the hemodynamic impact of a missed dose (particularly important in elderly patients who may occasionally miss doses), and avoids the reflex tachycardia associated with shorter-acting DHP CCBs; amlodipine is well-tolerated, requires no dose adjustment for age or renal function, and produces no metabolic or electrolyte adverse effects.
ANSWER: E
Rationale:
Among DHP CCBs, amlodipine has specific pharmacokinetic advantages that make it particularly well-suited for elderly ISH management. Its half-life of 35–50 hours is the longest of any commonly used DHP CCB — nifedipine XL has a much shorter effective half-life, felodipine approximately 11–16 hours, lercanidipine approximately 8–10 hours. This very long half-life confers several clinical advantages in elderly patients: it provides smooth, consistent 24-hour BP control with minimal peak-to-trough BP variation, avoiding the BP variability that independently predicts cardiovascular events; it creates a pharmacokinetic buffer against missed doses — if an elderly patient forgets one dose, plasma amlodipine concentrations decline slowly over days rather than hours, minimizing the risk of BP rebound; and it avoids the reflex tachycardia that shorter-acting DHP CCBs can produce. Amlodipine also has no dose adjustment requirement for age or renal function (hepatic metabolism, non-renally eliminated), no adverse metabolic effects (no hypokalemia, hyponatremia, hyperglycemia, or hyperuricemia), and no electrolyte disturbances. Peripheral edema is its primary adverse effect — more common in the elderly and managed by combination with a RAAS inhibitor.
Option A: Option A is incorrect because amlodipine has not been compared head-to-head with nifedipine or felodipine in elderly ISH-specific trials in the manner described — the preference for amlodipine is based on its pharmacokinetic properties, not on ISH-specific comparative trials.
Option B: Option B is incorrect because amlodipine does not have renoprotective properties equivalent to ACEi and ARBs — DHP CCBs dilate the afferent arteriole (potentially increasing glomerular pressure), while ACEi and ARBs dilate the efferent arteriole, reducing intraglomerular pressure and proteinuria; amlodipine is not preferred for CKD with albuminuria over RAAS inhibitors.
Option C: Option C is incorrect because amlodipine has minimal direct cardiac effects at standard doses — DHP CCBs in general have high vascular selectivity and do not significantly slow heart rate; negative chronotropy is a property of non-DHP CCBs (verapamil, diltiazem), not DHP CCBs.
Option D: Option D is incorrect because amlodipine's preference is pharmacologically substantiated by its unique long half-life — the pharmacological rationale is specific and clinically meaningful, not merely administrative.
11. Why is atenolol specifically identified as the beta-blocker most to be avoided in elderly patients with CKD, and what is the preferred alternative if a beta-blocker is required?
A) Atenolol is avoided in elderly CKD patients because it is metabolized by CYP3A4, which is upregulated in CKD, producing supratherapeutic plasma concentrations; bisoprolol is preferred because it is not CYP3A4-metabolized and maintains predictable plasma levels regardless of renal function.
B) Atenolol is avoided in elderly CKD patients because it crosses the blood-brain barrier, causing dementia and cognitive impairment — it is the most lipophilic beta-blocker and therefore the most neurotoxic; hydrophilic alternatives such as bisoprolol or nebivolol are preferred because they do not enter the CNS.
C) Atenolol is avoided because it is a non-selective beta-blocker — its beta-2 blockade in elderly patients with reduced respiratory reserve causes significant bronchoconstriction; bisoprolol is preferred because its beta-1 selectivity eliminates all pulmonary adverse effects.
D) Atenolol is renally eliminated and accumulates in CKD — in elderly patients with reduced eGFR (which may be substantially lower than serum creatinine suggests due to reduced muscle mass), atenolol plasma concentrations rise, producing excessive bradycardia, hypotension, and falls risk; atenolol also demonstrated inferior cardiovascular outcomes versus losartan in the LIFE trial for stroke prevention; bisoprolol is preferred in elderly CKD patients because it has dual hepatic and renal elimination, maintaining predictable pharmacokinetics across a range of eGFRs.
E) Atenolol is avoided in elderly CKD patients because it causes hyperkalemia through aldosterone suppression — its beta-1 blockade inhibits renin release, reducing angiotensin II and aldosterone, causing potassium retention that is particularly dangerous when added to the impaired potassium excretion of CKD; nebivolol is preferred because it has no effect on the renin-angiotensin-aldosterone system.
ANSWER: D
Rationale:
Atenolol is the beta-blocker most specifically identified as inappropriate in elderly patients with CKD for two independent reasons. First, pharmacokinetics: atenolol is eliminated almost entirely by renal excretion (greater than 85% excreted unchanged in urine) with minimal hepatic metabolism. In elderly patients, eGFR declines progressively with age — approximately 1 mL/min/year after age 40. Critically, muscle mass also decreases with age, meaning serum creatinine production falls; serum creatinine may appear deceptively normal while true GFR is substantially reduced. CKD-EPI equation-based eGFR assessment is essential because creatinine alone overestimates GFR in sarcopenic elderly patients. As eGFR declines, atenolol clearance falls proportionally, plasma concentrations accumulate, and the dose-related adverse effects — bradycardia, conduction block, hypotension, fatigue — intensify, directly increasing the risk of falls and syncope in a population already vulnerable to orthostatic events. Second, clinical outcomes: the LIFE trial (Losartan Intervention for Endpoint reduction in hypertension) demonstrated that atenolol-based therapy was inferior to losartan for stroke prevention in hypertensive patients with LVH — a finding that further supports avoiding atenolol as the default beta-blocker in elderly hypertension. Bisoprolol is preferred when a beta-blocker is required in elderly CKD patients because it has dual elimination (approximately 50% hepatic metabolism to inactive metabolites, 50% renal excretion) — as renal function declines, hepatic elimination partially compensates, maintaining more predictable pharmacokinetics. Nebivolol also has predominantly hepatic metabolism and is an acceptable alternative.
Option A: Option A is incorrect because atenolol is not metabolized by CYP3A4 — it is hydrophilic and renally excreted; CYP3A4 upregulation in CKD is not the mechanism of atenolol accumulation.
Option B: Option B is incorrect because atenolol is actually among the most hydrophilic (not lipophilic) beta-blockers — it crosses the blood-brain barrier minimally; the CNS adverse effect concern is with lipophilic beta-blockers (propranolol, metoprolol).
Option C: Option C is incorrect because atenolol is in fact a cardioselective (beta-1 selective) beta-blocker — it is not non-selective; the avoidance of atenolol is not based on beta-2 bronchoconstriction.
Option E: Option E is incorrect because while beta-1 blockade does reduce renin release (which can modestly affect aldosterone), hyperkalemia through aldosterone suppression is not the primary pharmacokinetic reason for avoiding atenolol in CKD — renal accumulation causing dose-related bradycardia and falls is the dominant concern.
12. Which of the following correctly describes the definition of orthostatic hypotension, its prevalence in the elderly, and the antihypertensive monitoring requirement it creates?
A) Orthostatic hypotension is defined as a fall in SBP of 20 mmHg or more, or a fall in DBP of 10 mmHg or more, within 3 minutes of standing from a supine or seated position; it affects approximately 20% of community-dwelling elderly and over 50% of institutionalized elderly; all antihypertensives can worsen orthostatic hypotension; BP should be measured in both sitting and standing positions at every visit in elderly hypertensive patients on antihypertensive therapy.
B) Orthostatic hypotension is defined as a fall in SBP of 10 mmHg or more within 30 seconds of standing — the 30-second measurement captures the most clinically significant early phase of orthostatic stress; prevalence is approximately 5% in the elderly.
C) Orthostatic hypotension in elderly hypertensive patients is caused exclusively by alpha-1 blockers and loop diuretics — thiazide diuretics, ACEi, ARBs, and DHP CCBs do not contribute to orthostatic hypotension and require no standing BP measurement; only patients on alpha-1 blockers or loop diuretics need orthostatic BP assessment.
D) Orthostatic hypotension monitoring requires a 24-hour ambulatory BP monitor with posture sensor — clinic BP measurement in sitting and standing positions is insufficient to detect clinically meaningful orthostatic hypotension because it fails to capture nocturnal orthostasis.
E) Orthostatic hypotension is defined as any BP reading below 120/70 mmHg in the standing position, regardless of the change from sitting — the absolute standing value, not the magnitude of change from baseline, determines the diagnosis and clinical significance.
ANSWER: A
Rationale:
Orthostatic hypotension (OH) is defined by standardized criteria: a fall in SBP of 20 mmHg or more, or a fall in DBP of 10 mmHg or more, within 3 minutes of standing from a supine or seated position. These are the criteria used in clinical guidelines and epidemiological research. The prevalence of OH is substantial in the elderly — approximately 20% of community-dwelling older adults — and rises to over 50% of institutionalized or hospitalized elderly patients, reflecting the contribution of dehydration, deconditioning, autonomic dysfunction, and polypharmacy. OH is associated with an approximately 2-fold increased risk of falls, syncope, and cardiovascular events. All antihypertensive drug classes can worsen OH — not only alpha-1 blockers and loop diuretics (which are most prominently associated) but also thiazide diuretics (volume depletion), ACEi and ARBs (reduced vasoconstrictor reserve), and DHP CCBs (peripheral vasodilation). This universal risk creates a specific monitoring requirement: BP must be checked in both sitting (or supine) and standing positions at every clinical visit in elderly hypertensive patients on antihypertensive therapy.
Option B: Option B is incorrect because the diagnostic criterion is a fall within 3 minutes of standing (not 30 seconds) and the threshold is SBP 20 mmHg (not 10 mmHg); and the prevalence of 5% substantially underestimates the true community prevalence of approximately 20%.
Option C: Option C is incorrect because all antihypertensive classes can contribute to orthostatic hypotension — not only alpha-1 blockers and loop diuretics; restricting standing BP assessment to patients on these two specific classes would miss the majority of drug-related OH in elderly patients.
Option D: Option D is incorrect because clinic measurement in sitting and standing positions is the standard clinical assessment for orthostatic hypotension — 24-hour ABPM with posture sensor is a research tool and is not required or standard of care for routine OH assessment.
Option E: Option E is incorrect because orthostatic hypotension is defined by the magnitude of BP fall from baseline (the change from sitting or supine), not by an absolute standing BP threshold — a patient with a baseline seated BP of 180/90 mmHg who stands and measures 160/80 mmHg has met the criteria for OH (20 mmHg SBP fall) even though the absolute standing values are elevated.
13. An 82-year-old man with ISH on amlodipine 10 mg and indapamide 1.25 mg develops significant bilateral ankle edema. His BP is well-controlled at 134/66 mmHg. Which of the following best describes the mechanism of CCB-induced edema and the most appropriate pharmacological management?
A) CCB-induced ankle edema is caused by sodium and water retention from renal tubular effects — amlodipine directly activates the NCC cotransporter in the distal tubule, promoting sodium reabsorption and volume expansion; switching to a thiazide-like diuretic with greater diuretic potency (chlorthalidone 25 mg) will overcome the CCB-mediated sodium retention.
B) CCB-induced ankle edema is caused by reduced cardiac output from the negative inotropic effects of amlodipine — reduced forward flow causes venous congestion and edema; the management is to add a loop diuretic (furosemide 40 mg) to overcome the cardiogenic edema.
C) CCB-induced peripheral edema results from arteriolar vasodilation without corresponding venodilation — preferential dilation of pre-capillary arterioles increases capillary hydrostatic pressure, driving fluid from the intravascular space into the interstitium; venoconstriction (not venodilation) persists, impairing fluid return; adding a RAAS inhibitor (ACEi or ARB) is pharmacologically appropriate — RAAS inhibitor-induced venodilation reduces venous pressure and helps reabsorb interstitial fluid, while the combination also provides additive antihypertensive benefit; alternatively, reducing the amlodipine dose may partially resolve the edema.
D) CCB-induced ankle edema is caused by direct toxicity to the lymphatic endothelium — amlodipine impairs lymphatic vessel contractility through calcium channel blockade in lymphatic smooth muscle, preventing lymphatic drainage from the lower extremities; compression stockings alone are the definitive treatment.
E) CCB-induced ankle edema is a sign of incipient heart failure from the negative inotropic effects of amlodipine — the edema represents fluid overload from reduced LV ejection fraction; the amlodipine must be stopped immediately and an echocardiogram obtained before any other antihypertensive can be prescribed.
ANSWER: C
Rationale:
CCB-induced peripheral edema (most prominently with DHP CCBs — amlodipine, nifedipine) is a pharmacodynamic consequence of selective arteriolar vasodilation without equivalent venodilation. DHP CCBs primarily dilate pre-capillary resistance arterioles, reducing systemic vascular resistance and lowering BP. However, they have minimal effect on post-capillary venules — venular tone is maintained or even slightly increased reflexively. The result is an imbalance: increased capillary inflow (from arteriolar vasodilation) with unchanged or reduced capillary outflow (venous return not augmented). This raises capillary hydrostatic pressure, driving net fluid movement from the intravascular compartment into the interstitial space — producing dependent edema that is most pronounced in the lower extremities in upright patients and is not caused by sodium or water retention. The pharmacological solution to this mechanism is addition of a RAAS inhibitor: ACEi and ARBs produce venodilation (through reduction of angiotensin II-mediated venular constriction), which restores the pre-capillary/post-capillary pressure balance and helps mobilize the interstitial fluid. This is why the CCB + ACEi/ARB combination (e.g., amlodipine + perindopril in the ASCOT-BPLA trial) is pharmacologically rational beyond its additive antihypertensive effect — the combination specifically reduces CCB-induced edema. Alternatively, reducing the amlodipine dose (e.g., from 10 mg to 5 mg) may partially reduce the edema while accepting some loss of BP control.
Option A: Option A is incorrect because CCB-induced edema is not caused by renal sodium retention — DHP CCBs actually have mild natriuretic properties; the mechanism is hemodynamic, not renal tubular; and switching to chlorthalidone would not address a hemodynamic edema mechanism.
Option B: Option B is incorrect because amlodipine has minimal negative inotropic effects at standard doses — it has high vascular selectivity; DHP CCB-induced edema is not cardiogenic and is not appropriately treated with furosemide, which would reduce the intravascular volume rather than correcting the capillary pressure imbalance.
Option D: Option D is incorrect because the mechanism of CCB-induced edema is arteriolar vasodilation increasing capillary hydrostatic pressure, not lymphatic dysfunction from calcium channel blockade in lymphatic muscle.
Option E: Option E is incorrect because amlodipine-induced ankle edema in the absence of dyspnea, elevated JVP, or other heart failure features is a drug adverse effect (hemodynamic edema), not a sign of incipient heart failure — DHP CCBs do not cause heart failure through negative inotropy; immediate discontinuation is not required.
14. Which of the following correctly describes the pharmacokinetic changes in the elderly that require modification of antihypertensive prescribing, and gives a specific example of a drug class affected?
A) The primary pharmacokinetic change in the elderly is increased hepatic first-pass metabolism — the elderly liver has accelerated CYP enzyme activity that rapidly clears antihypertensives, requiring higher doses of hepatically metabolized agents such as lisinopril and chlorthalidone to achieve equivalent plasma concentrations.
B) Age-related decline in GFR (approximately 1 mL/min/year after age 40), combined with reduced muscle mass that makes serum creatinine a poor surrogate for true GFR, causes accumulation of renally eliminated antihypertensives; atenolol (greater than 85% renally excreted) accumulates in elderly patients with CKD and causes excessive bradycardia and falls; the CKD-EPI equation provides a more accurate GFR estimate than serum creatinine alone in sarcopenic elderly patients; reduced hepatic blood flow and first-pass metabolism increases the oral bioavailability of high-extraction drugs such as labetalol, metoprolol, and amlodipine, potentially requiring lower initial doses.
C) The primary pharmacokinetic change in the elderly is increased plasma protein binding — elevated albumin in the elderly increases the protein-bound fraction of highly bound antihypertensives such as amlodipine and furosemide, reducing their free fraction and requiring substantially higher doses than in younger patients.
D) Age-related pharmacokinetic changes exclusively affect drug absorption — reduced gastric acid production in the elderly impairs dissolution of antihypertensive tablets, reducing bioavailability; all antihypertensives should therefore be given in liquid formulation to elderly patients.
E) The primary age-related pharmacokinetic change affecting antihypertensives is reduced volume of distribution — elderly patients have smaller total body water compartments, which increases peak plasma drug concentrations for all antihypertensives regardless of route of elimination, requiring uniform 50% dose reduction of all antihypertensives in patients aged 70 or older.
ANSWER: B
Rationale:
Multiple age-related physiological changes affect antihypertensive pharmacokinetics in the elderly, and understanding them is essential for safe prescribing. Renal function declines at approximately 1 mL/min/year after age 40, meaning an 80-year-old who developed CKD at age 40 may have a GFR of 40 mL/min — severely impaired. Critically, elderly patients often have substantially reduced muscle mass (sarcopenia), which reduces creatinine production; their serum creatinine may appear deceptively normal (e.g., 0.9 mg/dL) while true GFR is markedly reduced. The CKD-EPI equation — which incorporates age and sex in addition to serum creatinine — provides a significantly more accurate GFR estimate in elderly patients than serum creatinine alone. For renally eliminated drugs like atenolol, this reduced GFR means accumulation and dose-related toxicity. Hepatic changes also affect pharmacokinetics: reduced hepatic blood flow in the elderly reduces first-pass extraction of high-extraction drugs (labetalol, metoprolol, propranolol, nifedipine, amlodipine, verapamil, diltiazem), increasing oral bioavailability — the same dose produces higher peak plasma concentrations than in younger patients, warranting lower initial doses. Increased CNS sensitivity from altered blood-brain barrier function in aging increases the neurological effects of lipophilic drugs (lipophilic beta-blockers, centrally acting agents).
Option A: Option A is incorrect because hepatic CYP enzyme activity is generally reduced, not increased, in the elderly — and lisinopril and chlorthalidone are not significantly hepatically metabolized (lisinopril is renally excreted unchanged; chlorthalidone is minimally metabolized).
Option C: Option C is incorrect because plasma albumin is typically reduced (not increased) in elderly patients, particularly frail or malnourished ones — hypoalbuminemia increases the free fraction of highly protein-bound drugs, potentially increasing their pharmacological effect rather than requiring higher doses.
Option D: Option D is incorrect because gastric acid changes do not exclusively determine pharmacokinetics in the elderly — multiple absorptive and eliminative changes occur; and liquid formulations are not required for all elderly patients.
Option E: Option E is incorrect because a uniform 50% dose reduction for all elderly patients disregards the drug-specific nature of pharmacokinetic changes — not all antihypertensives require dose reduction; the approach must be drug-specific based on the elimination pathway.
15. An 84-year-old woman with ISH and no other comorbidities is on chlorthalidone 12.5 mg and amlodipine 5 mg. Her sitting BP is 136/64 mmHg and her standing BP is 112/52 mmHg — a 24/12 mmHg drop meeting the definition of orthostatic hypotension. She reports dizziness on rising and has had one fall in the past 3 months. Which of the following best describes the complete management plan?
A) Intensify antihypertensive therapy — the sitting BP of 136/64 mmHg is still above the ACC/AHA target of below 130/80 mmHg; adding a third agent to achieve the sitting target will reduce her overall cardiovascular risk enough to outweigh the orthostatic risk.
B) Add midodrine 2.5 mg three times daily as first-line treatment for her orthostatic hypotension — midodrine is the initial pharmacological intervention of choice for all elderly patients with OH before any antihypertensive modification is attempted.
C) Reduce chlorthalidone to 6.25 mg — thiazide diuretics are the sole contributor to orthostatic hypotension in this patient; the amlodipine does not contribute and should be maintained at 5 mg; after reducing chlorthalidone, no other interventions are needed.
D) Switch amlodipine to a beta-blocker — the peripheral vasodilation from amlodipine is causing the orthostatic drop; replacing it with a cardioselective beta-blocker will eliminate the vasodilatory contributor to OH while maintaining BP control.
E) Simplify and reduce the antihypertensive regimen — given her sitting BP of 136/64 mmHg is reasonably controlled, the orthostatic drop to 112/52 mmHg, her fall history, and her age (84 years, CFS likely 4–5), the primary concern is fall risk from drug-induced orthostatic hypotension; appropriate steps include reducing amlodipine to 2.5 mg or reducing chlorthalidone to 6.25 mg (or both), relaxing her sitting SBP target toward 140–150 mmHg consistent with ESH 2023 guidance for patients aged 80 or older, and implementing non-pharmacological measures including advice on slow positional changes, adequate hydration, and timing of doses away from morning rising; falls risk assessment and physiotherapy referral should accompany the pharmacological change.
ANSWER: E
Rationale:
This patient's clinical picture calls for de-escalation of antihypertensive therapy rather than intensification. At 84 years with a 24 mmHg orthostatic SBP drop (meeting the definition of OH), a fall in the past 3 months, and a standing SBP of 112 mmHg — which compromises cerebral perfusion on position change — the dominant risk at this moment is falls and injury, not cardiovascular events from imperfectly controlled sitting BP. Her sitting SBP of 136 mmHg is close to the ESH 2023 recommended target of 140–149 mmHg for patients aged 80 or older; there is no pressing need to push it lower. The complete pharmacological management includes: reducing one or both antihypertensives to lighten the overall antihypertensive burden (amlodipine from 5 mg to 2.5 mg, or chlorthalidone from 12.5 mg to 6.25 mg, or both); relaxing the sitting SBP target toward 140–150 mmHg; timing doses away from morning when OH is most pronounced (orthostatic hypotension is worst in the morning due to overnight recumbency and dehydration); and implementing non-pharmacological strategies. Physiotherapy referral for falls risk assessment and exercise to improve postural control is an important non-pharmacological component.
Option A: Option A is incorrect because intensifying antihypertensive therapy in a patient with documented symptomatic orthostatic hypotension and a recent fall is clinically harmful — it would worsen the OH and increase falls risk; the sitting BP of 136 mmHg does not require further lowering in an 84-year-old with these complications.
Option B: Option B is incorrect because midodrine — a peripheral alpha-1 agonist vasopressor used for refractory OH — is not the first-line intervention; the initial approach is antihypertensive dose reduction and non-pharmacological measures; midodrine can also raise supine BP dangerously in elderly patients.
Option C: Option C is incorrect because both agents contribute to orthostatic hypotension — chlorthalidone causes volume depletion and amlodipine causes arteriolar vasodilation that impairs the standing blood pressure response; attributing OH solely to chlorthalidone and maintaining amlodipine at 5 mg is clinically incomplete.
Option D: Option D is incorrect because switching amlodipine to a beta-blocker does not address the orthostatic problem effectively — beta-blockers reduce heart rate reserve, which is the compensatory mechanism that helps maintain BP during positional changes; in an elderly patient with OH, reducing heart rate reserve with a beta-blocker would likely worsen orthostatic events, not improve them.
16. Which of the following correctly describes why alpha-1 blockers such as doxazosin are not recommended as antihypertensive monotherapy in elderly patients, and when they have a legitimate clinical role?
A) Alpha-1 blockers are not recommended as antihypertensive monotherapy in the elderly because they cause reflex tachycardia — the peripheral vasodilation from alpha-1 blockade produces compensatory sympathetic activation that raises heart rate to dangerous levels in elderly patients with limited cardiac reserve.
B) Alpha-1 blockers are not recommended as antihypertensive monotherapy in the elderly because they cause hyperkalemia — blockade of alpha-1 receptors in the adrenal cortex reduces aldosterone secretion, causing potassium retention that is particularly dangerous in elderly patients with CKD.
C) Alpha-1 blockers are not recommended as antihypertensive monotherapy in the elderly primarily because they cause hypercalcemia — alpha-1 receptor blockade in the parathyroid gland increases PTH secretion, raising serum calcium; the hypercalcemia risk is amplified by concurrent thiazide diuretic use.
D) Alpha-1 blockers are not recommended as antihypertensive monotherapy in the elderly because they cause orthostatic hypotension and first-dose syncope, which are disproportionately dangerous in a population already at high risk of falls and hip fracture; the ALLHAT trial demonstrated increased heart failure rates with doxazosin as monotherapy compared with chlorthalidone; their legitimate clinical role in the elderly is as add-on therapy — not monotherapy — in elderly men with concurrent benign prostatic hyperplasia (BPH), where dual benefit (BP lowering plus urinary symptom relief) may justify use when initiated at the lowest dose at bedtime and titrated slowly.
E) Alpha-1 blockers are not recommended as antihypertensive monotherapy in the elderly because they cause cognitive impairment through direct CNS alpha-1 blockade — alpha-1 receptors in the prefrontal cortex regulate working memory, and their blockade by doxazosin causes irreversible cognitive decline in elderly patients with pre-existing small vessel disease.
ANSWER: D
Rationale:
Alpha-1 blockers (doxazosin, terazosin, prazosin) are associated with two specific adverse effects that are particularly dangerous in the elderly. First-dose syncope: the initial dose of an alpha-1 blocker produces acute peripheral vasodilation that can cause profound orthostatic hypotension — elderly patients with reduced baroreceptor sensitivity and reduced cardiovascular compensatory reserve are unable to mount an adequate heart rate and cardiac output response, precipitating syncope and falls. Orthostatic hypotension is a persistent issue throughout treatment, not just at the first dose, because the mechanism of BP lowering (peripheral arteriolar and venodilation) directly impairs standing BP maintenance. The clinical consequences — falls, hip fracture, subdural hematoma — are disproportionately severe in the elderly. The ALLHAT trial (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) specifically demonstrated that doxazosin as monotherapy produced significantly more cardiovascular events, particularly heart failure, compared with chlorthalidone; the doxazosin arm was terminated early for this reason. The legitimate role of alpha-1 blockers in elderly men is as add-on therapy for dual indication — BP management plus symptomatic BPH relief (where alpha-1 receptor blockade relaxes prostatic and urethral smooth muscle). Even in this context, the lowest available dose at bedtime is used to minimize the peak vasodilatory effect during ambulation.
Option A: Option A is incorrect because alpha-1 blockers cause reflex tachycardia in some patients, but this is not the primary reason for avoiding them in the elderly — the primary concerns are orthostatic hypotension, falls, and the ALLHAT heart failure data.
Option B: Option B is incorrect because alpha-1 receptor blockade does not significantly reduce aldosterone secretion — aldosterone is primarily regulated by angiotensin II and serum potassium, not by adrenal alpha-1 receptors; hyperkalemia is not a prominent adverse effect of alpha-1 blockers.
Option C: Option C is incorrect because alpha-1 blockers do not cause hypercalcemia through PTH effects — this mechanism is pharmacologically fabricated.
Option E: Option E is incorrect because doxazosin does not cause irreversible cognitive decline through prefrontal alpha-1 receptor blockade — this mechanism is fabricated; while centrally acting agents (clonidine, methyldopa) cause sedation and cognitive effects through central mechanisms, peripheral alpha-1 blockers like doxazosin do not cross the blood-brain barrier extensively enough to produce irreversible cognitive impairment through this mechanism.
17. What is the Syst-Eur trial's specific contribution to elderly hypertension pharmacology, and how does it complement the SHEP trial?
A) Syst-Eur enrolled 4,695 patients aged 60 or older with ISH and randomized them to nitrendipine (a DHP CCB)-based therapy versus placebo, demonstrating a 42% reduction in stroke, 31% reduction in all cardiovascular events, and 26% reduction in cardiac endpoints — complementing SHEP by establishing DHP CCBs as effective first-line agents for ISH in the elderly through a renin-independent mechanism, providing evidence-based support for CCBs alongside thiazide-like diuretics as the two cornerstone drug classes for elderly ISH.
B) Syst-Eur enrolled patients aged 80 or older and demonstrated that nitrendipine produced superior stroke reduction compared to indapamide — establishing CCBs as the preferred class over diuretics for very elderly patients.
C) Syst-Eur was the first trial to demonstrate that antihypertensive treatment in elderly patients increases dementia risk — nitrendipine-based therapy produced a significant increase in Alzheimer's disease incidence, leading to its withdrawal from the market.
D) Syst-Eur demonstrated that nitrendipine was equivalent to placebo for stroke prevention but superior for MI prevention — establishing that DHP CCBs are the preferred class for coronary artery disease prevention but not for stroke prevention in elderly ISH.
E) Syst-Eur tested nitrendipine versus chlorthalidone head-to-head and demonstrated chlorthalidone's superiority — this trial is misquoted as supporting CCBs when in fact it established diuretics as the definitive first-line agents in elderly ISH.
ANSWER: A
Rationale:
Syst-Eur (Systolic Hypertension in Europe, 1997) was a placebo-controlled trial enrolling 4,695 patients aged 60 or older with ISH (SBP 160–219 mmHg, DBP below 95 mmHg) and randomizing them to nitrendipine-based therapy (with possible addition of enalapril and HCTZ if needed) versus placebo. Key results: 42% reduction in stroke (the primary endpoint), 31% reduction in all cardiovascular events, and 26% reduction in cardiac endpoints. The trial was stopped early for benefit. Syst-Eur's contribution to elderly ISH pharmacology is specific and complementary to SHEP: SHEP established thiazide-like diuretics (chlorthalidone) as effective first-line agents in elderly ISH through a trial published in 1991. Syst-Eur, published six years later, established DHP CCBs (nitrendipine) as an equally effective first-line class through a mechanistically distinct pathway — DHP CCBs lower BP through L-type calcium channel-mediated arteriolar vasodilation, a renin-independent mechanism that is particularly effective in the low-renin, volume-dependent hypertension of elderly ISH. Together, SHEP and Syst-Eur provide the dual evidence base that places thiazide-like diuretics and DHP CCBs as the two preferred first-line classes for elderly ISH.
Option B: Option B is incorrect because Syst-Eur enrolled patients aged 60 or older (not only 80 or older — that was HYVET), and it was not a head-to-head comparison of nitrendipine versus indapamide; it was nitrendipine versus placebo.
Option C: Option C is incorrect because Syst-Eur did not demonstrate increased dementia risk — in fact, a secondary analysis of Syst-Eur data suggested a potential reduction in dementia incidence with CCB-based treatment; and nitrendipine was not withdrawn from markets because of this trial.
Option D: Option D is incorrect because Syst-Eur demonstrated significant stroke reduction as its primary endpoint (42%) — the trial does not show equivalence to placebo for stroke prevention.
Option E: Option E is incorrect because Syst-Eur was not a head-to-head comparison of nitrendipine versus chlorthalidone — it was a placebo-controlled trial; it specifically supports CCBs, not diuretics.
18. Which of the following correctly describes the concept of de-prescribing in elderly hypertension and identifies the clinical triggers that should prompt consideration of reducing or withdrawing antihypertensive therapy?
A) De-prescribing of antihypertensives in the elderly is never appropriate — once antihypertensive therapy is initiated, it must be maintained indefinitely regardless of changes in the patient's functional status, frailty progression, or development of adverse effects; withdrawing therapy always increases cardiovascular risk.
B) De-prescribing of antihypertensives in the elderly is appropriate only when the patient requests it — clinicians should not proactively suggest medication reduction because the cardiovascular risk of withdrawal invariably outweighs any quality-of-life benefit; patient-initiated requests are the only valid trigger.
C) De-prescribing — active, planned reduction or withdrawal of antihypertensive medications — is a legitimate and important clinical strategy in the elderly, particularly in frail patients; appropriate triggers include: recurrent falls attributable to orthostatic hypotension or syncope from antihypertensive medications; severe symptomatic orthostatic hypotension causing functional limitation; advancing frailty (CFS 6–8) where the life expectancy is insufficient to derive cardiovascular benefit from tight BP control and quality of life is the primary goal; multiple antihypertensives causing adverse effects that outweigh their benefits; and patient or carer preference after informed discussion of the risks and benefits of continued therapy.
D) De-prescribing of antihypertensives is appropriate only in patients with terminal illness with a prognosis of less than 3 months — in all other elderly patients, antihypertensives should be maintained at full therapeutic doses regardless of adverse effects, as any BP elevation from withdrawal causes immediate cardiovascular harm.
E) De-prescribing should be approached by abrupt discontinuation of all antihypertensives simultaneously — gradual tapering is unnecessary as antihypertensives do not cause physiological dependence; sudden withdrawal simply restores the pre-treatment BP without any rebound risk.
ANSWER: C
Rationale:
De-prescribing — the planned, supervised reduction or withdrawal of medications when the harm outweighs the benefit in the context of the individual patient's goals, life expectancy, and current clinical status — is a well-established clinical strategy in geriatric pharmacology, and antihypertensives are among the most commonly de-prescribed drug classes in the very elderly. The clinical triggers that appropriately prompt de-prescribing of antihypertensives include: recurrent falls or syncope attributable to orthostatic hypotension — falls can cause hip fracture, subdural hematoma, and death, consequences that may outweigh the long-term cardiovascular benefit of tight BP control; severe symptomatic orthostatic hypotension causing significant functional limitation (inability to ambulate independently, restricted activities of daily living); advancing frailty (CFS 6–8) where the patient's life expectancy is insufficient to capture the long-term cardiovascular benefit of BP reduction (most cardiovascular trials accrue benefit over 3–5 years) and where the immediate harms of polypharmacy are substantial; polypharmacy-related adverse effects from multiple antihypertensives causing cognitive impairment, electrolyte disturbances, or reduced quality of life; and patient or carer preference after fully informed shared decision-making. De-prescribing requires monitoring and appropriate tapering for certain agents (notably beta-blockers and centrally acting agents, which can cause rebound hypertension or tachycardia on abrupt discontinuation).
Option A: Option A is incorrect because de-prescribing is a legitimate, guideline-endorsed clinical strategy in elderly patients — not all antihypertensive therapy should be continued indefinitely regardless of clinical circumstances.
Option B: Option B is incorrect because clinicians should proactively identify patients who may benefit from de-prescribing and raise the discussion — waiting for patient-initiated requests misses many opportunities to reduce medication harm in frail elderly patients.
Option D: Option D is incorrect because de-prescribing is not limited to terminal patients with prognosis below 3 months — frail elderly patients at much earlier stages of clinical decline, or patients experiencing significant medication-related harm, are appropriate candidates for antihypertensive de-prescribing.
Option E: Option E is incorrect because abrupt discontinuation of all antihypertensives simultaneously is clinically dangerous — beta-blockers and centrally acting agents (clonidine in particular) can cause severe rebound hypertension and tachycardia on abrupt withdrawal; gradual tapering with BP monitoring is required.
19. Which of the following correctly describes why NSAIDs are particularly problematic in elderly hypertensive patients and the specific pharmacological interactions they produce?
A) NSAIDs are problematic in elderly hypertensive patients because they inhibit CYP3A4, reducing the metabolism of amlodipine, lisinopril, and chlorthalidone — plasma concentrations of all antihypertensives rise, causing excessive BP lowering and orthostatic hypotension.
B) NSAIDs antagonize the antihypertensive effects of diuretics and RAAS inhibitors through prostaglandin inhibition — renal prostaglandins (PGE2, PGI2) promote natriuresis and maintain renal perfusion in states of reduced effective circulating volume; COX inhibition by NSAIDs reduces prostaglandin synthesis, causing sodium and water retention that directly opposes the natriuretic effect of diuretics and increases vascular tone; NSAIDs also reduce the vasodilatory and natriuretic response to RAAS inhibition; in elderly patients already at risk for AKI, this effect can precipitate acute kidney injury; NSAIDs used chronically for musculoskeletal pain are a common and under-recognized cause of resistant hypertension in older patients.
C) NSAIDs are problematic in elderly hypertensive patients exclusively because they inhibit platelet COX-1, increasing thromboxane A2 and causing vasoconstriction — this effect is additive with norepinephrine-mediated vasoconstriction and raises BP; switching to a selective COX-2 inhibitor completely eliminates this mechanism and is safe in elderly hypertensive patients.
D) NSAIDs cause hypertension in elderly patients through direct mineralocorticoid receptor activation — ibuprofen and naproxen bind the mineralocorticoid receptor in the kidney, producing aldosterone-like sodium retention; spironolactone specifically blocks this NSAID-mineralocorticoid receptor interaction and is the preferred antihypertensive add-on when NSAIDs cannot be avoided.
E) NSAIDs are problematic in elderly hypertensive patients only when they are taken at maximum therapeutic doses — low-dose ibuprofen (200 mg once daily) is pharmacologically equivalent to acetaminophen for analgesia and carries no antihypertensive drug interactions in elderly patients.
ANSWER: B
Rationale:
NSAIDs are one of the most clinically important pharmacological antagonists of antihypertensive therapy in the elderly, and identifying their use is a standard component of resistant hypertension evaluation. The mechanism is prostaglandin-mediated. In healthy individuals, renal prostaglandins (particularly PGE2 and PGI2) play a modulatory role in natriuresis and renal hemodynamics. In states of reduced effective circulating volume — which elderly patients on diuretics often experience — renal prostaglandins become critical for maintaining adequate renal perfusion through their vasodilatory effects on afferent arterioles and their opposition to angiotensin II-mediated vasoconstriction. NSAIDs inhibit COX-1 and COX-2 in the kidney, reducing prostaglandin synthesis. The consequences: sodium and water retention (directly opposing diuretic effect), increased vascular tone (opposing RAAS inhibitor vasodilation), and reduced renal perfusion — which in the context of already-compromised renal reserve in elderly patients can precipitate AKI. The clinical effect is blunting of the antihypertensive response and elevation of BP — often by 3–5 mmHg on average, but more substantially in individual patients. NSAIDs for musculoskeletal pain (osteoarthritis is ubiquitous in the elderly) are a common and under-recognized cause of apparent resistant hypertension. Medication reconciliation at every visit must specifically ask about NSAID use, including over-the-counter ibuprofen and naproxen.
Option A: Option A is incorrect because NSAIDs do not inhibit CYP3A4 significantly — their mechanism of drug interaction in hypertension is prostaglandin-mediated renal sodium retention, not CYP inhibition.
Option C: Option C is incorrect because the mechanism of NSAID-induced hypertension is not platelet COX-1 inhibition and thromboxane A2 — it is renal prostaglandin synthesis inhibition causing sodium retention; additionally, selective COX-2 inhibitors (celecoxib, rofecoxib) still affect renal prostaglandins and carry similar or greater cardiovascular and antihypertensive-antagonism risks compared with non-selective NSAIDs.
Option D: Option D is incorrect because NSAIDs do not bind the mineralocorticoid receptor — their renal effects are via prostaglandin inhibition, not MR agonism; spironolactone is not the specific antidote for NSAID-related BP elevation.
Option E: Option E is incorrect because even low-dose NSAIDs have clinically meaningful renal prostaglandin effects and antihypertensive antagonism — there is no safe "low-dose" threshold below which NSAID-antihypertensive interactions are pharmacologically irrelevant in elderly patients.
20. An 80-year-old man with ISH and no CKD is started on chlorthalidone 12.5 mg daily per HYVET-based protocol. Which monitoring parameters are specifically required and at what interval?
A) No specific monitoring is required after initiating chlorthalidone in elderly patients — routine annual physical examination is sufficient; laboratory monitoring is necessary only if the patient develops symptoms.
B) Monthly serum potassium only is required — chlorthalidone's primary adverse effect is hypokalemia and potassium is the only electrolyte of concern; sodium levels do not need to be checked as SIADH from thiazides is extremely rare.
C) Uric acid should be measured every 2 weeks for the first 3 months — chlorthalidone-induced hyperuricemia is the most important adverse effect in elderly men and requires the most intensive monitoring; potassium and sodium are secondary concerns.
D) Serum creatinine and potassium should be checked at 4 weeks; no sodium monitoring is required as hyponatremia from chlorthalidone is primarily a concern in younger women, not elderly men.
E) Sodium, potassium, creatinine, and sitting and standing BP should be checked within 2–4 weeks of initiating chlorthalidone in an elderly patient — hyponatremia risk is highest in the first 2–4 weeks (the period of maximal natriuresis before compensatory mechanisms equilibrate), hypokalemia monitoring is standard, creatinine assesses for AKI from volume contraction, and sitting-plus-standing BP checks for orthostatic hypotension; chlorthalidone should be initiated at the lowest effective dose (6.25–12.5 mg) in elderly patients.
ANSWER: E
Rationale:
Chlorthalidone initiation in an elderly patient requires specific early monitoring because the most dangerous adverse effects manifest in the first weeks of treatment. Hyponatremia: the risk of thiazide-induced hyponatremia is highest in the first 2–4 weeks after initiation, when natriuresis is maximal and compensatory mechanisms (aldosterone response, thirst-driven fluid intake) have not yet equilibrated. Elderly women are at highest risk, but elderly men are also at meaningfully elevated risk compared with younger patients. Presenting serum sodium before initiation and rechecking at 2–4 weeks is essential to detect early hyponatremia before it becomes symptomatic (confusion, lethargy, falls, seizures at extreme levels). Hypokalemia: chlorthalidone's sustained diuresis causes potassium wasting through increased distal tubular sodium delivery stimulating aldosterone-mediated potassium secretion; potassium monitoring at 2–4 weeks identifies this and guides supplementation or dietary advice. Creatinine and eGFR: volume contraction from diuresis can reduce effective renal perfusion and cause a functional rise in creatinine — monitoring allows early detection of AKI, particularly relevant in elderly patients with baseline CKD or reduced renal reserve. Sitting and standing BP: the antihypertensive effect should be confirmed and orthostatic hypotension assessed — the standing BP assessment is particularly important given the high prevalence of OH in the elderly and the volume-depleting effect of the diuretic. Chlorthalidone should be started at the lowest effective dose in the elderly (6.25–12.5 mg) to minimize these risks.
Option A: Option A is incorrect because specific early monitoring is clearly indicated — the risks of hyponatremia, hypokalemia, AKI, and orthostatic hypotension in the first weeks require laboratory and clinical assessment before annual follow-up.
Option B: Option B is incorrect because sodium monitoring is equally important to potassium — hyponatremia from thiazide diuretics is a serious, clinically significant adverse effect in elderly patients and not extremely rare; restricting monitoring to potassium alone misses the hyponatremia risk.
Option C: Option C is incorrect because while hyperuricemia from chlorthalidone is a real concern (particularly relevant if the patient has a history of gout), it is not the primary monitoring priority; uric acid does not require fortnightly assessment, and potassium and sodium are monitored first.
Option D: Option D is incorrect because sodium monitoring is specifically indicated in elderly patients on chlorthalidone — hyponatremia risk is not limited to younger women; elderly men also face elevated risk compared to younger patients.
21. Which of the following best describes the appropriate BP target and treatment approach for an 85-year-old woman with ISH who lives independently, has Clinical Frailty Scale 3 (managing well), and a sitting BP averaging 168/62 mmHg?
A) No treatment is indicated — above age 80, antihypertensive therapy is not evidence-based and HYVET enrolled an unrepresentative population; all patients above age 85 should be managed with lifestyle modification alone.
B) The target should be SBP below 120 mmHg per SPRINT — SPRINT enrolled patients above 75 years and demonstrated clear mortality benefit at this target; age 85 is within the SPRINT evidence base and intensive targeting is appropriate.
C) The target should be below 130/80 mmHg per ACC/AHA 2017 — this guideline applies to all community-dwelling ambulatory adults aged 65 or older without qualification for frailty; an 85-year-old with CFS 3 is sufficiently fit for this aggressive target.
D) The appropriate target for this fit 85-year-old is SBP 140–149 mmHg, consistent with ESH 2023 guidance for patients aged 80 or older; first-line treatment is chlorthalidone 6.25–12.5 mg or amlodipine 2.5–5 mg initiated at the low end with the start-low, go-slow principle; avoid reducing DBP below 65 mmHg given her already-low baseline DBP of 62 mmHg; standing BP should be assessed at each visit; indapamide ± perindopril (the HYVET regimen) is an evidence-based alternative first-line option.
E) The appropriate target is SBP 160 mmHg — in patients aged 85 or older, treatment is indicated only when SBP exceeds 160 mmHg and the treatment goal is simply to bring SBP to just below this threshold; any SBP below 160 mmHg at age 85 requires no treatment regardless of cardiovascular risk.
ANSWER: D
Rationale:
This 85-year-old independent woman with CFS 3 (managing well, not frail) has a sitting SBP averaging 168/62 mmHg — well above the treatment threshold and warranting treatment with a clinically meaningful target. The appropriate target is guided by ESH 2023, which recommends an SBP of 140–149 mmHg for patients aged 80 or older (with lower targets of 130–139 mmHg considered if tolerated without adverse effects). For a CFS 3 patient — fit but acknowledging her age — the ESH target of 140–149 mmHg provides the balance between cardiovascular protection (established in HYVET at a mean achieved SBP of 143.5 mmHg) and avoidance of the J-curve risk (her baseline DBP is already 62 mmHg — close to the 65 mmHg lower limit of safety for coronary perfusion). The start-low, go-slow principle mandates initiating at the lowest effective dose: chlorthalidone 6.25 mg or amlodipine 2.5 mg, with titration every 4–6 weeks rather than every 2–4 weeks as in younger patients. The HYVET regimen (indapamide SR 1.5 mg ± perindopril 2–4 mg) is an equally appropriate evidence-based first-line choice.
Option A: Option A is incorrect because HYVET specifically enrolled patients aged 80 or older (mean 83.6 years) and demonstrated clear cardiovascular and mortality benefit — antihypertensive treatment has a strong evidence base above age 80; age 85 is directly within the HYVET population.
Option B: Option B is incorrect because SPRINT's target of below 120 mmHg (AOBP) corresponds to approximately 130 mmHg by conventional measurement — and more importantly, this patient's DBP of 62 mmHg means any significant SBP reduction risks further lowering DBP below the 65 mmHg J-curve threshold; intensive SPRINT-style targeting is not appropriate when baseline DBP is already marginal.
Option C: Option C is incorrect because the ACC/AHA 2017 guideline itself acknowledges that higher targets may be appropriate for frail elderly patients; even for a CFS 3 patient at age 85, the ESH 2023 target of 140–149 mmHg for patients aged 80 or older is more specifically tailored to this age group and more aligned with the HYVET evidence.
Option E: Option E is incorrect because the treatment threshold in guidelines is 160 mmHg SBP for initiation in some elderly-specific guidance, but the treatment target is not simply "just below 160 mmHg" — the target is 140–149 mmHg (ESH) or below 130 mmHg (ACC/AHA) depending on frailty; the goal is meaningful reduction, not marginal improvement.
22. Which of the following correctly summarizes the BP target differences between ACC/AHA 2017 and ESH 2023 guidelines for elderly patients, and the clinical reason for the divergence?
A) ACC/AHA 2017 recommends below 130/80 mmHg for community-dwelling ambulatory adults aged 65 or older, based primarily on the SPRINT trial; ESH 2023 recommends SBP 130–139 mmHg for ages 65–79 and SBP 140–149 mmHg for ages 80 or older (with lower targets considered if well-tolerated); the divergence reflects different interpretations of the SPRINT methodology (AOBP vs. conventional measurement) and different weightings of frailty, J-curve risk, and the HYVET evidence base, with ESH giving greater emphasis to individualization in the very elderly.
B) ACC/AHA 2017 and ESH 2023 are identical in their elderly BP targets — both recommend below 130/80 mmHg for all elderly patients regardless of age; the apparent differences are a labeling artifact from different BP measurement methods that produce equivalent absolute targets.
C) ACC/AHA 2017 recommends below 140/90 mmHg for all elderly patients; ESH 2023 recommends below 130/80 mmHg — the ESH is more aggressive than ACC/AHA for the elderly population, reflecting European trial data showing greater benefit from intensive control.
D) Both guidelines recommend withholding antihypertensive treatment above age 80 unless SBP exceeds 180 mmHg — the HYVET trial's modest p-value for stroke reduction (p=0.06) was interpreted by both guideline committees as insufficient evidence for routine treatment in the very elderly.
E) ESH 2023 recommends beta-blockers as the preferred first-line agent for all elderly patients based on heart rate reduction reducing pulse pressure in ISH; ACC/AHA 2017 recommends thiazide diuretics exclusively; the divergence reflects different interpretations of the SHEP trial's atenolol add-on arm.
ANSWER: A
Rationale:
The divergence between ACC/AHA 2017 and ESH 2023 targets for elderly patients reflects genuine differences in the interpretation of available evidence and the weighting of different clinical considerations. ACC/AHA 2017 adopted an ambitious target of below 130/80 mmHg for community-dwelling ambulatory adults aged 65 or older, driven substantially by the SPRINT trial's demonstration of cardiovascular and mortality benefit at intensive targets in the elderly subgroup. ESH 2023 adopted a more graduated approach: SBP 130–139 mmHg for ages 65–79 (broadly consistent with ACC/AHA) and SBP 140–149 mmHg for ages 80 or older, reflecting the HYVET evidence base (which achieved a mean SBP of 143.5 mmHg in the active treatment arm), the J-curve risk of excessive DBP lowering in elderly CAD patients, greater emphasis on frailty individualization, and concern about the AOBP measurement method used in SPRINT producing values 5–10 mmHg lower than conventional office BP — meaning SPRINT's 120 mmHg target is not equivalent to 120 mmHg by standard measurement. Both guidelines agree that treatment in the elderly is beneficial and indicated, but differ on how aggressively to target and how to individualize for very elderly and frail patients. Clinicians should be aware of both frameworks and apply the one most consistent with their patient's individual profile, frailty status, and comorbidities.
Option B: Option B is incorrect because ACC/AHA and ESH targets for elderly patients are genuinely different and clinically meaningful, not just a measurement labeling artifact — the divergence reflects real differences in evidence interpretation and frailty weighting.
Option C: Option C is incorrect because it reverses the relative aggressiveness — ACC/AHA (below 130/80 mmHg) is more aggressive than ESH for the very elderly (140–149 mmHg for age 80+), not less so; ESH is not more aggressive for the elderly.
Option D: Option D is incorrect because both guidelines recommend treatment in the very elderly — HYVET's total mortality reduction was statistically significant (p=0.02) and heart failure reduction was dramatic (64%); neither guideline withholds treatment above age 80 pending a SBP of 180 mmHg.
Option E: Option E is incorrect because neither guideline recommends beta-blockers as preferred first-line for all elderly patients — both recommend thiazide-like diuretics and DHP CCBs as first-line for elderly ISH; beta-blockers are reserved for patients with compelling indications.
BEFORE YOU MOVE ON
The pharmacology of elderly hypertension rewards careful individualization — the same drug class that reduces stroke risk in one patient increases fall risk in another. The core framework to carry forward: ISH is driven by arterial stiffness, not neurohormonal activation; SHEP and Syst-Eur provide the cornerstone trial evidence for chlorthalidone and DHP CCBs; HYVET established that treatment above age 80 is both beneficial and well-tolerated; frailty fundamentally modifies the risk-benefit calculation and should guide target selection; orthostatic hypotension requires standing BP assessment at every visit; the J-curve mandates attention to DBP when treating elderly patients with CAD or wide pulse pressure; and de-prescribing is as pharmacologically legitimate as prescribing when adverse effects outweigh benefit. The Tier 1 questions will build these principles into clinical decision-making scenarios.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.